Literature DB >> 14638552

Robust adenoviral and adeno-associated viral gene transfer to the in vivo murine heart: application to study of phospholamban physiology.

Hunter C Champion1, Dimitrios Georgakopoulos, Saptarsi Haldar, Lili Wang, Yibin Wang, David A Kass.   

Abstract

BACKGROUND: Viral gene transfer to the whole heart in vivo has been achieved in several mammalian species but remained difficult to accomplish in murine hearts. We postulated that a key impediment derives from the use of proximal aortic occlusion during virus injection, because this eliminates coronary perfusion gradients in mice as aortic root and left ventricle pressures equalize. METHODS AND
RESULTS: Pressure-volume analysis confirmed these mechanics. In contrast, descending aortic occlusion with whole-body cooling (20 degrees C) preserved transmyocardial perfusion gradients and allowed for sustained (>10-minute) dwell times in an upper-body perfusion circuit. This approach yielded robust cardiac transfection with adenovirus (AdV) and adeno-associated virus (AAV) injected into the left ventricle cavity or more simply via a central vein. Cardio-specific expression was achieved with a myocyte-specific promotor. Optimal AdV transfection required 9-minute aortic occlusion, versus 5-minute occlusion for AAV. Using this method, we examined the in vivo function of phospholamban (PLB) by stably transfecting PLB-null mice with AAV encoding PLB (AAV(PLB)). AAV(PLB) restored PLB protein to near control levels that colocalized with SERCA2A in cardiomyocytes. At baseline, PLB-null hearts exhibited enhanced systolic and diastolic function, but frequency-dependent reserve was blunted versus wild-type controls. These properties, particularly the frequency response, returned toward control 3 months after AAV(PLB) transfection.
CONCLUSIONS: The new simplified approach for murine whole-heart viral transfection should assist molecular physiology studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638552     DOI: 10.1161/01.CIR.0000096487.88897.9B

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  22 in total

1.  Frequency-dependent acceleration of relaxation in mammalian heart: a property not relying on phospholamban and SERCA2a phosphorylation.

Authors:  Carlos A Valverde; Cecilia Mundiña-Weilenmann; Matilde Said; Paola Ferrero; Leticia Vittone; Margarita Salas; Julieta Palomeque; Martín Vila Petroff; Alicia Mattiazzi
Journal:  J Physiol       Date:  2004-11-04       Impact factor: 5.182

Review 2.  Creating a cardiac pacemaker by gene therapy.

Authors:  Traian M Anghel; Steven M Pogwizd
Journal:  Med Biol Eng Comput       Date:  2006-12-01       Impact factor: 2.602

Review 3.  Rescuing the failing heart by targeted gene transfer.

Authors:  Yoshiaki Kawase; Dennis Ladage; Roger J Hajjar
Journal:  J Am Coll Cardiol       Date:  2011-03-08       Impact factor: 24.094

Review 4.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

Review 5.  Myocardial gene transfer: routes and devices for regulation of transgene expression by modulation of cellular permeability.

Authors:  Michael G Katz; Anthony S Fargnoli; Charles R Bridges
Journal:  Hum Gene Ther       Date:  2013-04-01       Impact factor: 5.695

6.  Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts.

Authors:  Ioannis Karakikes; Lahouaria Hadri; Kleopatra Rapti; Dennis Ladage; Kiyotake Ishikawa; Lisa Tilemann; Geng-Hua Yi; Charlotte Morel; Judith K Gwathmey; Krisztina Zsebo; Thomas Weber; Yoshiaki Kawase; Roger J Hajjar
Journal:  Mol Ther       Date:  2012-01-03       Impact factor: 11.454

7.  PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury.

Authors:  Tomohisa Nagoshi; Takashi Matsui; Takuma Aoyama; Annarosa Leri; Piero Anversa; Ling Li; Wataru Ogawa; Federica del Monte; Judith K Gwathmey; Luanda Grazette; Brian A Hemmings; Brian Hemmings; David A Kass; Hunter C Champion; Anthony Rosenzweig
Journal:  J Clin Invest       Date:  2005-07-07       Impact factor: 14.808

8.  Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

Authors:  Lennart Suckau; Henry Fechner; Elie Chemaly; Stefanie Krohn; Lahouaria Hadri; Jens Kockskämper; Dirk Westermann; Egbert Bisping; Hung Ly; Xiaomin Wang; Yoshiaki Kawase; Jiqiu Chen; Lifan Liang; Isaac Sipo; Roland Vetter; Stefan Weger; Jens Kurreck; Volker Erdmann; Carsten Tschope; Burkert Pieske; Djamel Lebeche; Heinz-Peter Schultheiss; Roger J Hajjar; Wolfgang C Poller
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

9.  Full-length dystrophin expression in half of the heart cells ameliorates beta-isoproterenol-induced cardiomyopathy in mdx mice.

Authors:  Yongping Yue; Jeffrey W Skimming; Mingju Liu; Tammy Strawn; Dongsheng Duan
Journal:  Hum Mol Genet       Date:  2004-06-09       Impact factor: 6.150

10.  Targeted high-efficiency, homogeneous myocardial gene transfer.

Authors:  Tetsuo Sasano; Kan Kikuchi; Amy D McDonald; Shenghan Lai; J Kevin Donahue
Journal:  J Mol Cell Cardiol       Date:  2007-02-14       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.